Peter J. Larson

3.5k total citations · 2 hit papers
43 papers, 2.4k citations indexed

About

Peter J. Larson is a scholar working on Hematology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Peter J. Larson has authored 43 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 10 papers in Molecular Biology and 7 papers in Infectious Diseases. Recurrent topics in Peter J. Larson's work include Hemophilia Treatment and Research (14 papers), Blood Coagulation and Thrombosis Mechanisms (9 papers) and Blood properties and coagulation (4 papers). Peter J. Larson is often cited by papers focused on Hemophilia Treatment and Research (14 papers), Blood Coagulation and Thrombosis Mechanisms (9 papers) and Blood properties and coagulation (4 papers). Peter J. Larson collaborates with scholars based in United States, United Kingdom and Denmark. Peter J. Larson's co-authors include Katherine A. High, Roland W. Herzog, Linda B. Couto, Catherine S. Manno, Alan W. Flake, Erik D. Skarsgard, Shing Jen Tai, Bertil Glader, Margaret V. Ragni and Alan McClelland and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Peter J. Larson

41 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector

2000 782 citations Mark A. Kay, Catherine S. Manno et al. profile →
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B

2003 578 citations Catherine S. Manno, S Hutchison et al. Blood profile →

Peers

Countries citing papers authored by Peter J. Larson

Since Specialization

Citations

This map shows the geographic impact of Peter J. Larson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Larson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Larson more than expected).

Fields of papers citing papers by Peter J. Larson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Larson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Larson. The network helps show where Peter J. Larson may publish in the future.

Co-authorship network of co-authors of Peter J. Larson

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Larson. A scholar is included among the top collaborators of Peter J. Larson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Larson. Peter J. Larson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug delivery systems for wound healing treatment of upper airway injury 2024 ·Expert Opinion on Drug Delivery ·D. Cruz, (unknown), Tilahun Ayane Debele, Peter J. Larson, Gregory R. Dion, (unknown)	5
2	Engineering a “detect and destroy” skin probiotic to combat methicillin-resistant Staphylococcus aureus 2022 ·PLoS ONE ·Changhui Guan, Peter J. Larson, Elizabeth Fleming, Alexander P. Tikhonov, (unknown), Trudy H. Grossman, (unknown), Julia Oh	12
3	Associations of the skin, oral and gut microbiome with aging, frailty and infection risk reservoirs in older adults 2022 ·Nature Aging ·Peter J. Larson, Wei Zhou, Alba Santiago, (unknown), Elizabeth Fleming, Anita Y. Voigt, Ock K. Chun, James J. Grady, George A. Kuchel, Julie Robison, Julia Oh	54
4	Challenges in Developing a Human Model System for Skin Microbiome Research 2020 ·Journal of Investigative Dermatology ·Peter J. Larson, (unknown), Elizabeth Fleming, Julia Oh	27
5	Host-Specific Evolutionary and Transmission Dynamics Shape the Functional Diversification of Staphylococcus epidermidis in Human Skin 2020 ·Cell ·Wei Zhou, (unknown), Rachel Hardy, Changhui Guan, Elizabeth Fleming, Peter J. Larson, Joseph S. Brown, Julia Oh	96
6	Intestinal Bile Acids Induce a Morphotype Switch in Vancomycin-Resistant Enterococcus that Facilitates Intestinal Colonization 2019 ·Cell Host & Microbe ·Peter T. McKenney, Jinyuan Yan, Julien Vaubourgeix, Simone Becattini, Nina Lampen, (unknown), Peter J. Larson, (unknown), Sho Fujisawa, João B. Xavier, Eric G. Pamer	46
7	Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Sharon Walmsley, Anchalee Avihingsanon, Jihad Slim, Douglas Ward, Kiat Ruxrungtham, Jason Brunetta, U. Fritz Bredeek, Dushyantha Jayaweera, (unknown), Peter J. Larson, Malte Schütz, François Raffi	76
8	Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept®, Roche): overview 2009 ·AIDS Research and Therapy ·Anton Pozniak, Lutz Müller, Miklos Salgo, Judith K. Jones, Peter J. Larson, David Tweats	16
9	An Open-Label Safety Study of Enfuvirtide Injection with a Needle-Free Injection Device or Needle/Syringe: The Biojector 2000 Open-Label Safety Study (BOSS) 2008 ·AIDS Research and Human Retroviruses ·Jacob Lalezari, Michael S. Saag, (unknown), Peter J. Larson	6
10	Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A 2005 ·Thrombosis and Haemostasis ·Joan Cox Gill, Chantal Rothschild, Marilyn J. Manco‐Johnson, (unknown), (unknown), Eduard Gorina, Peter J. Larson, W. Kreuz, (unknown)	79
11	Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand 2004 ·Haemophilia ·Jeffrey S. Stonebraker, (unknown), (unknown), (unknown), Peter J. Larson	17
12	Development and validation of a measure of disease‐specific quality of life in young children with haemophilia 2004 ·Haemophilia ·M. Manco‐Johnson, (unknown), (unknown), Gerry Oster, Peter J. Larson	33
13	AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B breakdown → 2003 ·Blood ·Catherine S. Manno, (unknown), S Hutchison, Peter J. Larson, Roland W. Herzog, (unknown), Shing Jen Tai, Margaret V. Ragni, Alexis A. Thompson, Margareth C. Ozelo, Linda B. Couto, Debra G. B. Leonard, Freddie A. Johnson, Alan McClelland, Ciaran D. Scallan, Erik D. Skarsgard, Alan W. Flake, Mark A. Kay, Katherine A. High, Bertil Glader	578
14	Health‐related quality of life assessment in adult haemophilia patients: a systematic review and evaluation of instruments 2003 ·Haemophilia ·Ágota Szende, W. Schramm, Emuella Flood, Peter J. Larson, Eduard Gorina, Anne M. Rentz, Laurie D. Snyder	43
15	Virtual Environments for Targeting Cognitive Processes: An Overview of Projects at the University of Southern California 1999 ·CyberPsychology & Behavior ·(unknown), J. Galen Buckwalter, Ulrich Neumann, Clint Chua, André van Rooyen, Peter J. Larson, (unknown), Carl Kesselman, Marcus Thiébaux, L. Humphrey	17
16	Gender Issues in the Use of Virtual Environments 1999 ·CyberPsychology & Behavior ·Peter J. Larson, A. A. Rizzo, J. Galen Buckwalter, André van Rooyen, (unknown), Ulrich Neumann, Carl Kesselman, Marcus Thiébaux, C. van der Zaag	36
17	The Virtual Reality Mental Rotation Spatial Skills Project 1998 ·CyberPsychology & Behavior ·Albert Rizzo, J. Galen Buckwalter, Ulrich Neumann, Carl Kesselman, Marcus Thiébaux, Peter J. Larson, André van Rooyen	35
18	The presurgical management with erythrocytapheresis of a patient with a high‐oxygen‐affinity, unstable Hb variant (Hb Bryn Mawr) 1997 ·Transfusion ·Peter J. Larson, David F. Friedman, Michael P. Reilly, (unknown), Toshio Asakura, Paolo Fortina, Alan R. Cohen, Haewon C. Kim, Catherine S. Manno	8
19	Delayed hemolytic transfusion reaction due to anti-Goa, an antibody against the low-prevalence Gonzales antigen 1996 ·American Journal of Hematology ·Peter J. Larson, (unknown), David F. Friedman, Catherine S. Manno	16
20	Structural Integrity of the γ-Carboxyglutamic Acid Domain of Human Blood Coagulation Factor IXa Is Required for Its Binding to Cofactor VIIIa 1996 ·Journal of Biological Chemistry ·Peter J. Larson, (unknown), William J. VanDusen, Carol K. Kasper, Kenneth J. Smith, Dougald M. Monroe, Katherine A. High	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact